Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.53 |
| ▸ | CACNG8 | Q8WXS5 | 5/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TERT | O14746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539960 | 0.81 | GRIA1 (0.46) | GRIA1CACNG8PDE3BPDE3AGAA | |
| SCHEMBL13680594 | 0.78 | NOS1 (0.58) | PDE3BPDE3ALMNAGSK3B | |
| SCHEMBL13680599 | 0.76 | CA12 (0.54) | PDE3BPDE3AMAPTTHRBGSK3B | |
| SCHEMBL13680976 | 0.73 | MAPT (0.50) | GRIA1CACNG8PDE3BPDE3AGAA | |
| SCHEMBL13680597 | 0.71 | ALDH1A1 (0.55) | PDE3BPDE3AGAAMAPTTP53 | |
| SCHEMBL23197679 | 0.71 | TDP1 (0.56) | GAAMAPTLMNATDP1GSK3B | |
| SCHEMBL18551785 | 0.70 | BRD4 (0.50) | GSK3B | |
| SCHEMBL13680470 | 0.70 | NPC1 (0.50) | GAA | |
| SCHEMBL1180863 | 0.70 | JAK2 (0.55) | GSK3B | |
| SCHEMBL8264638 | 0.69 | GRIA1 (0.65) | GRIA1CACNG8PDE3BPDE3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050979-A1 | SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASES POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-02-23 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050979-A1 | SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASES POLYPEPTIDES | GRK6, GRK2, GRK3 | GRIA1 17/4885CACNG8 791/4885PDE3B 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.